In this issue:
Genome sequencing in myeloid cancers
Pirtobrutinib in R/R B-cell malignancies
Rituximab + high-dose chemo in aggressive B-cell lymphoma
4 Gy vs 24 Gy RT for follicular and marginal zone lymphoma
Optimal number of chemo courses in young patients with AML
Allo HSCT improves DFS in adult ALL
Polatuzumab vedotin for R/R aggressive B-cell lymphoma
Does ALK mutation impact consolidative RT benefit in PTCL?
End-of-treatment PET/CT predicts PFS and OS in DLBCL
R-CEOP shows curative potential in DLBCL
Please login below to download this issue (PDF)